MWNA
ACRS icon

Marshall Wace North America’s Aclaris Therapeutics ACRS Stock Holding History

Marshall Wace North America’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-380,959
Closed -$5.53M – 1448
2018
Q3 		$5.53M Sell
380,959
-150,251
-28% -$2.58M 0.04% 295
2018
Q2 		$10.6M Sell
531,210
-155,381
-23% -$2.87M 0.06% 322
2018
Q1 		$12M Sell
686,591
-47,725
-6% -$1.01M 0.06% 355
2017
Q4 		$18.1M Sell
734,316
-80,289
-10% -$1.96M 0.1% 250
2017
Q3 		$21.2M Sell
814,605
-67,692
-8% -$1.81M 0.13% 203
2017
Q2 		$23.8M Buy
882,297
+178,436
+25% +$4.85M 0.17% 150
2017
Q1 		$21.1M Buy
+703,861
New +$20.3M 0.17% 172

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Marshall Wace North America's ACRS Position: Q4 2018 in Review

Marshall Wace North America sold out of Aclaris Therapeutics (ACRS) in Q4 2018, closing a stake of 380,959 shares — an estimated $5.53M sold.

Marshall Wace North America first reported a position in ACRS in Q1 2017 and held it in 7 quarters. The position peaked at $23.8M in Q2 2017. 99 funds tracked by Wall St. Rank hold ACRS as of Q4 2018.

  • Marshall Wace North America reported no remaining Aclaris Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Marshall Wace North America sold 380,959 Aclaris Therapeutics shares in Q4 2018, an estimated $5.53M.
  • Marshall Wace North America first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 7 quarters.
  • Marshall Wace North America's Aclaris Therapeutics position peaked at $23.8M in Q2 2017.
  • 99 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2018.

Based on Marshall Wace North America's 13F filing for Q4 2018, filed 14 Feb 2019.